Equity Investment Corp raised its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 4.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,008,448 shares of the company’s stock after buying an additional 81,015 shares during the quarter. Sanofi comprises 3.6% of Equity Investment Corp’s investment portfolio, making the stock its 7th largest holding. Equity Investment Corp owned approximately 0.08% of Sanofi worth $109,300,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the business. Fairfield Bush & CO. bought a new stake in shares of Sanofi during the first quarter valued at approximately $26,000. Bank of New York Mellon Corp increased its position in shares of Sanofi by 31.3% during the first quarter. Bank of New York Mellon Corp now owns 440,646 shares of the company’s stock valued at $22,623,000 after purchasing an additional 105,046 shares during the period. Cambridge Investment Research Advisors Inc. increased its position in shares of Sanofi by 12.9% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 24,613 shares of the company’s stock valued at $1,264,000 after purchasing an additional 2,805 shares during the period. Yousif Capital Management LLC increased its position in shares of Sanofi by 45.2% during the first quarter. Yousif Capital Management LLC now owns 42,041 shares of the company’s stock valued at $2,158,000 after purchasing an additional 13,095 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Sanofi by 0.5% in the first quarter. Dimensional Fund Advisors LP now owns 300,009 shares of the company’s stock valued at $15,402,000 after acquiring an additional 1,391 shares during the period. 10.67% of the stock is currently owned by institutional investors and hedge funds.
Sanofi Trading Down 2.0 %
Shares of SNY traded down $1.06 during trading hours on Friday, hitting $52.48. 3,204,574 shares of the stock traded hands, compared to its average volume of 1,696,024. The company has a current ratio of 1.42, a quick ratio of 1.05 and a debt-to-equity ratio of 0.20. Sanofi has a 1-year low of $36.91 and a 1-year high of $57.82. The firm has a market capitalization of $132.36 billion, a PE ratio of 18.81, a price-to-earnings-growth ratio of 1.64 and a beta of 0.58. The business has a fifty day moving average of $52.58 and a 200-day moving average of $52.80.
Sanofi (NASDAQ:SNY – Get Free Report) last issued its quarterly earnings results on Thursday, April 27th. The company reported $1.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.06. Sanofi had a return on equity of 28.45% and a net margin of 15.41%. The business had revenue of $10.97 billion for the quarter, compared to analyst estimates of $11.60 billion. Analysts expect that Sanofi will post 4.46 EPS for the current year.
Sanofi Cuts Dividend
The company also recently declared an annual dividend, which was paid on Friday, June 23rd. Stockholders of record on Wednesday, May 31st were paid a dividend of $1.377 per share. This represents a dividend yield of 2.94%. The ex-dividend date of this dividend was Tuesday, May 30th. Sanofi’s dividend payout ratio (DPR) is presently 49.46%.
Analyst Ratings Changes
A number of analysts have weighed in on SNY shares. Deutsche Bank Aktiengesellschaft cut Sanofi from a “hold” rating to a “sell” rating in a research report on Friday, April 28th. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 13th. Finally, HSBC assumed coverage on Sanofi in a report on Friday, July 14th. They set a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $87.83.
Sanofi Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.